Mainstay Capital Management LLC ADV lessened its stake in shares of AstraZeneca plc (NYSE:AZN) by 23.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,829 shares of the company’s stock after selling 1,830 shares during the period. Mainstay Capital Management LLC ADV’s holdings in AstraZeneca were worth $291,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in AZN. Prime Capital Investment Advisors LLC purchased a new stake in AstraZeneca during the 3rd quarter valued at $34,000. Manchester Financial Inc. purchased a new stake in AstraZeneca in the fourth quarter worth $42,000. Allred Capital Management LLC purchased a new stake in AstraZeneca in the fourth quarter worth $43,000. Venturi Wealth Management LLC purchased a new stake in AstraZeneca in the third quarter worth $46,000. Finally, Simon Quick Advisors LLC increased its stake in AstraZeneca by 1,515.0% in the fourth quarter. Simon Quick Advisors LLC now owns 969 shares of the company’s stock worth $48,000 after purchasing an additional 909 shares during the period. Institutional investors own 17.45% of the company’s stock.
A number of analysts have weighed in on the company. Leerink Swann assumed coverage on AstraZeneca in a research note on Friday, November 22nd. They issued an “outperform” rating and a $57.00 target price on the stock. Cowen reiterated an “outperform” rating and issued a $55.00 target price (up previously from $48.00) on shares of AstraZeneca in a research note on Monday, December 2nd. ValuEngine lowered AstraZeneca from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 8th. Zacks Investment Research lowered AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 3rd. Finally, Svb Leerink assumed coverage on AstraZeneca in a research note on Friday, November 22nd. They issued an “outperform” rating on the stock. Five research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average price target of $50.35.
AZN stock opened at $51.33 on Tuesday. The firm has a market cap of $134.68 billion, a price-to-earnings ratio of 62.60, a PEG ratio of 1.53 and a beta of 0.46. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 1.29. AstraZeneca plc has a twelve month low of $35.30 and a twelve month high of $51.55. The business’s fifty day simple moving average is $49.57 and its two-hundred day simple moving average is $45.85.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.45 by $0.05. The firm had revenue of $6.13 billion for the quarter, compared to analyst estimates of $6.07 billion. AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.71 earnings per share. Research analysts expect that AstraZeneca plc will post 1.81 EPS for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is Depreciation?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.